"The US Food and Drug Administration (FDA) today issued detailed guidance on deferring blood donations from individuals who may harbor the Zika virus, strongly suspected of causing congenital microcephaly and Guillain-BarrĂ© syndrome.
Cefotaxime Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Cefotaxime for injection is a cephalosporin antibiotic used to treat a variety of bacterial infections. Cefotaxime is available in generic form. Common side effects of cefotaxime include:
- injection site reactions (pain, irritation, a hard lump, or inflammation),
- stomach pain,
- vaginal itching or discharge, and
Less common side effects of cefotaxime include:
- low white blood cell levels,
- low blood platelet levels, and
- yeast infection.
Dosage of cefotaxime is determined by susceptibility of the causative organisms, severity of the infection, and the condition of the patient. Cefotaxime may interact with aminoglycoside antibiotics. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or planning to become pregnant before using cefotaxime. This drug passes into breast milk in low concentrations. Consult your doctor before breastfeeding.
Our cefotaxime for injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Cefotaxime FDA Prescribing Information: Side Effects
Cefotaxime (cefotaxime for injection) is generally well tolerated. The most common adverse reactions have been local reactions following IV injection. Other adverse reactions have been encountered infrequently.
The most frequent adverse reactions (greater than 1%) are:
Local (4.3%)— Injection site inflammation with IV administration.
Hypersensitivity (2.4%)—Rash, pruritus, fever, eosinophilia and less frequently urticaria and anaphylaxis.
Gastrointestinal (1.4%)—Colitis, diarrhea, nausea, and vomiting.
Symptoms of pseudomembranous colitis can appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Less frequent adverse reactions (less than 1%) are:
Cardiovascular System—Potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration via central venous catheter have been observed.
Hematologic System—Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and agranulocytosis have been reported. Some individuals have developed positive direct Coombs Tests during treatment with cefotaxime (cefotaxime for injection) and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
Genitourinary System—Moniliasis, vaginitis.
Central Nervous System—Headache, encephalopathy.
Liver—Transient elevations in SGOT, SGPT, serum LDH, and serum alkaline phosphatase levels have been reported.
Kidney—As with some other cephalosporins, interstitial nephritis and transient elevations of BUN and creatinine have been occasionally observed with cefotaxime (cefotaxime for injection) .
Cutaneous—As with other cephalosporins, isolated cases of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported.
Cephalosporin Class Labeling
In addition to the adverse reactions listed above which have been observed in patients treated with cefotaxime (cefotaxime for injection) sodium, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: allergic reactions, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and false-positive test for urinary glucose.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. See DOSAGE AND ADMINISTRATION and OVERDOSAGE. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Read the entire FDA prescribing information for Cefotaxime (Cefotaxime for Injection)
Additional Cefotaxime Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.